Abstract:Two thirds of breast cancers express estrogen receptors (ER). ER alpha (ERα) mediates breast cancer cell proliferation, and expression of ERα is the standard choice to indicate adjuvant endocrine therapy. ERbeta (ERβ) inhibits growth in vitro; its effects in vivo have been incompletely investigated and its role in breast cancer and potential as alternative target in endocrine therapy needs further study. In this work, mammary epithelial (EpH4 and HC11) and breast cancer (MC4-L2) cells with endogenous ERα and ERβ expression and T47-D human breast cancer cells with recombinant ERβ (T47-DERβ) were used to explore effects exerted in vitro and in vivo by the ERβ agonists 2,3-bis (4–hydroxy–phenyl)-propionitrile (DPN) and 7-bromo-2-(4–hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY). In vivo, ERβ agonists induced mammary gland hyperplasia and MC4-L2 tumour growth to a similar extent as the ERα agonist 4,4′,4′′-(4-propyl-(1H)-pyrazole-1,3,5-triyl) trisphenol (PPT) or 17β-estradiol (E2) and correlated with higher number of mitotic and lower number of apoptotic features. In vitro, in MC4-L2, EpH4 or HC11 cells incubated under basal conditions, ERβ agonists induced apoptosis measured as upregulation of p53 and apoptosis-inducible factor protein levels and increased caspase 3 activity, whereas PPT and E2 stimulated proliferation. However, when extracellular signal-regulated kinase 1 and 2 (ERK ½) were activated by co-incubation with basement membrane extract or epidermal growth factor, induction of apoptosis by ERβ agonists was repressed and DPN induced proliferation in a similar way as E2 or PPT. In a context of active ERK ½, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/RAC-alpha serine/threonine-protein kinase (AKT) signalling was necessary to allow proliferation stimulated by ER agonists. Inhibition of MEK ½ with UO126 completely restored ERβ growth-inhibitory effects, whereas inhibition of PI3K by LY294002 inhibited ERβ-induced proliferation. These results show that the cellular context modulates ERβ growth-inhibitory effects and should be taken into consideration upon assessment of ERβ as target for endocrine treatment.

Tectoridin, a poor ligand of estrogen receptor α, exerts its estrogenic effects via an ERK-dependent pathway

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

Ginsenoside Rg1 Exerts Estrogen-Like Activities Via Ligand-Independent Activation of ERα Pathway

Receptor mediated biological activities of phytoestrogens

Mitogen-activated protein kinase (MAPK) pathway mediates the oestrogen-like activities of ginsenoside Rg1 in human breast cancer (MCF-7) cells.

Inhibitory actions of genistein in human breast cancer (MCF-7) cells

Genistein'S "Er-Dependent and Independent" Actions Are Mediated Through Er Pathways in Er-Positive Breast Carcinoma Cell Lines

In-vitro Estrogenic Effect of the bis(4-hydroxybenzyl)ether Extracted from Gastrodia elata Blume

Toll-Like Receptor 9 Agonist Inhibits Er Alpha-Mediated Transactivation by Activating Nf-Kappa B in Breast Cancer Cell Lines

Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation.

The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures

Flavonoid Effects Relevant to Cancer

Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer

Estrogen Transactivates Egfr Via The Sphingosine 1-Phosphate Receptor Edg-3: The Role Of Sphingosine Kinase-1

Activation of insulin-like growth factor I receptor-mediated pathway by ginsenoside Rg1.

Glycone-rich Soy Isoflavone Extracts Promote Estrogen Receptor Positive Breast Cancer Cell Growth

Tectorigenin: A Review of Its Sources, Pharmacology, Toxicity, and Pharmacokinetics

Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines

Intratumoral Estrogen Sulfotransferase Induction Contributes to the Anti-Breast Cancer Effects of the Dithiocarbamate Derivative TM208.

Tectoridin Inhibits Osteoclastogenesis and Bone Loss in a Murine Model of Ovariectomy-Induced Osteoporosis

Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells